Immunitas therapeutics address
Witryna0001193125-23-095201.txt : 20240407 0001193125-23-095201.hdr.sgml : 20240407 20240407160257 ACCESSION NUMBER: 0001193125-23-095201 CONFORMED SUBMISSION TYPE: PRE 14A PUBLIC DOCUME Witryna15 kwi 2024 · Immunitas uses a single cell sequencing platform to identify novel oncology targets. The company is currently advancing a number of programs toward early human studies, including IMT-009, which targets CD161, a therapeutic T and NK cell target recently highlighted in the journal Cell. IMT-009 is a monoclonal antibody …
Immunitas therapeutics address
Did you know?
WitrynaGet Verified Emails for 53 Immunitas Therapeutics Employees. 5 free lookups per month. No credit card required. The most common Immunitas Therapeutics email format is [first_initial] [last] (ex. [email protected]), which is being used by 100.0% of Immunitas Therapeutics work email addresses. WitrynaImmunitas was founded to directly address this problem and unlock a variety of novel drug targets based on discovery rooted in human biology. They are pursuing this goal with a team of pioneers in these areas across their scientific founders, management, and investors.At Immunitas, they employ a single cell sequencing platform to dissect the ...
Witryna5 sty 2024 · HiFiBiO Therapeutics. HiFiBiO Therapeutics is a multinational biotherapeutics company mobilizing the human immune system to combat disease. The company integrates biological expertise with its single-cell profiling technologies to discover and advance a pipeline of antibody drugs to treat cancer and autoimmune … WitrynaImmunitas Therapeutics is a single cell genomics-based drug discovery company that modulates oncology targets. Cambridge, Massachusetts, United States; 1-10; ...
Witryna18 sie 2024 · WALTHAM, Mass., Aug. 18, 2024 /PRNewswire/ -- Immunitas Therapeutics ("Immunitas"), a single cell genomics-based therapeutics company, … Witryna31 mar 2024 · Immunitas Therapeutics Closes $58M in Series B Financing. By FinSMEs Published on August 19, 2024 August 19, 2024. France. ... Email address: Leave this field empty if you're human:
Witryna药明康德内容团队编辑. 2024年8月18日，Immunitas Therapeutics公司宣布完成5800万美元的B轮融资。获得资金将用于推进其治疗实体瘤和血液癌症的新型自然杀 …
Witryna5 paź 2024 · WALTHAM, Mass., Oct. 5, 2024 /PRNewswire/ -- Immunitas Therapeutics ("Immunitas"), a precision immunotherapy company committed to discovering and … church in africa collectionhttp://www.kanaphtx.com/kr/about/about.php devon shores beach suitesWitrynaI am a computational scientist at Immunitas Therapeutics where I apply computational and statistical methods to single-cell RNA-seq and … church in africaWitrynaABOUT. Kanaph Therapeutics is a biotech with activities that range from drug discovery to early stage clinical trials. We are dedicated to developing next generation therapeutics for oncology and autoimmune diseases. Our oncology pipeline includes bi-specific antibodies and small molecules that have a greatly enhanced immuno … church in adelaideWitryna18 sie 2024 · “Immunitas has made tremendous strides in the past year. This Series B financing is a key inflection point for the company and will enable us to drive IMT-009 rapidly into the clinic, while continuing to build and validate our pipeline of novel oncology programs,” said Jeffrey Goldberg, Chief Executive Officer of Immunitas Therapeutics ... devon shoresWitrynaGet Seng-Lai Tan's email address (t*****@immunitastx.com) and phone number (317-915-....) at RocketReach. Get 5 free searches. devon shores nhlWitryna15 kwi 2024 · Basel, Switzerland, 15 April 2024 – Lonza and Immunitas Therapeutics today announced an agreement to advance the manufacturing process for the company's lead drug candidate, IMT-009, using a customized, accelerated version of Lonza's Ibex ® Design program. Under the terms of the agreement, Lonza's Ibex ® Design end-to … church in agra